Commentary Open Access
Volume 2 | Issue 5 | DOI: https://doi.org/10.33696/immunology.2.053
Sofosbuvir/Velpatasvir/Voxilaprevir for Previously DAA-treated Patients with Chronic Hepatitis C?
Llaneras J1,2,*, Riveiro-Barciela M2,3, Esteban R2,3, Buti M2,3
- 1Emergency Room Department, Vall d’Hebron University Hospital, Barcelona, Department of Medicine of UAB (Universitat Autònoma de Barcelona), Spain
- 2Liver Unit, Internal Medicine Department, Vall d’Hebron University Hospital, Barcelona, Spain
- 3Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto Carlos III, Barcelona,Spain
Corresponding Author
Llaneras J, jllanera@vhebron.net
Received Date: July 21, 2020
Accepted Date: August 26, 2020
Llaneras J, Riveiro-Barciela M, Esteban R, Buti M. Sofosbuvir/Velpatasvir/Voxilaprevir for Previously DAA-treated Patients with Chronic Hepatitis C? J Cell Immunol. 2020; 2(5): 259-264.
Copyright: © 2020 Llaneras J, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Recommended Articles
Karyotypic Profile of Chronic Myeloid Leukemia in Patients Diagnosed at Tertiary Level in Afghanistan
Balanced translocation resulting in fusion of the Abelson gene (ABL1) from chromosome 9q34 with the breakpoint cluster region (BCR) gene on chromosome 22q11.2 is the pathognomonic molecular driver of CML. The resulting BCRABL 1 fusion gene is both the diagnostic as well as therapeutic target of CML. The first agent with tyrosine kinase inhibitor activity that was licenced in 2000 for treatment of CML patients, was Imatinib, gradually followed by multiple agents with higher efficacy.
Prevalence of Symptom Clusters in Cancer Patients at First Presentation in Palliative Care Clinic as per Different Disease Groups
Cancer has its own disease burden and patients usually suffer from symptom clusters when they are referred for palliative treatment. Identification of symptom cluster trajectories will help clinician to take into account measures that can optimize quality of life of palliative patients. Therefore the aim of this paper is to determine the overall prevalence of symptoms and symptoms clusters in different disease groups according to etiology at the time of first visit to Palliative care clinic by using HIS Palliative First Assessment note indicating Edmonton symptom scale.
Therapeutic Values of Ketamine for COVID-19-Cared Patients: An Expert’s Point of View
Ketamine has long been used in the field of anesthesia [1]. Its rapid and long-acting analgesic effects associated with its dissociative properties have also established its use in prehospital and emergency department patients.
Prospective Evaluation of Effect of Metformin on Activation of AMP-activated Protein Kinase (AMPK) and Disease Control in a Sub-group Analysis of Patients with GI Malignancies
Observational studies have demonstrated association of metformin with reduced cancer incidence and mortality in multiple cancer types, including gastrointestinal (GI) malignancies. Anti-neoplastic effects of metformin are believed through many mechanisms including activation of AMP-activated protein kinase, which controls mammalian target of rapamycin (mTOR) growth regulatory pathway.
Interviewing Techniques for Patients with Intellectual Disability
Levels of Intellectual Disability and Categories of Communicative Skills When conducting a patient interview, it is crucial to understand the individuals’ level of ID as well as their expressive language skills in order to communicate effectively